Patents by Inventor Andrew John Timothy George

Andrew John Timothy George has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anticoagulant fusion protein anchored to cell membrane
    Patent number: 9376684
    Abstract: The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: June 28, 2016
    Assignee: Imperial Innovations Limited
    Inventors: Kristian Riesbeck, Anthony Dorling, Andrew John Timothy George, Robert Ian Lechler
  • Anticoagulant Fusion Protein Anchored to Cell Membrane
    Publication number: 20120017288
    Abstract: The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).
    Type: Application
    Filed: March 17, 2011
    Publication date: January 19, 2012
    Inventors: Kristian Riesbeck, Anthony Dorling, Andrew John Timothy George, Robert Ian Lechler
  • Anticoagulant fusion protein anchored to cell membrane
    Patent number: 6423316
    Abstract: The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).
    Type: Grant
    Filed: February 2, 2000
    Date of Patent: July 23, 2002
    Assignee: Imperial College Innovative Limited
    Inventors: Kristian Riesbeck, Anthony Dorling, Andrew John Timothy George, Robert Ian Lechler